Product Overview

Reepag 1 contains Repaglinide, a meglitinide class oral antidiabetic medication developed for the effective management of Type 2 Diabetes Mellitus. It is primarily indicated for adults whose blood glucose levels cannot be adequately controlled through diet, exercise, and lifestyle modifications alone. Repaglinide is particularly effective in controlling postprandial (after-meal) blood glucose levels by stimulating rapid insulin release in response to food intake.

Unlike long-acting insulin secretagogues, Repaglinide has a rapid onset and short duration of action, making it well suited for mealtime glucose management. It allows insulin secretion to closely mimic the body’s natural physiological response to meals, helping improve overall glycemic control while offering flexibility in dosing schedules.

Reepag 1 may be prescribed as monotherapy or in combination with other oral antidiabetic medications such as Metformin when additional blood glucose control is required. It is intended to be used alongside a balanced diet, regular physical activity, and routine blood glucose monitoring as part of a comprehensive diabetes management plan.

Manufactured under stringent pharmaceutical quality standards, Reepag 1 delivers consistent efficacy, safety, and reliability, making it a trusted therapeutic option for healthcare professionals managing Type 2 Diabetes Mellitus.

How It Works

Repaglinide stimulates the pancreatic beta cells to release insulin in response to rising blood glucose levels after meals. Its rapid onset of action helps control postprandial blood glucose excursions, while its short duration of action reduces prolonged insulin stimulation, supporting effective and flexible glycemic management.

Therapeutic Applications

Reepag 1 may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Postprandial Blood Glucose Control
• Long-Term Glycemic Management
• Combination Therapy with other Antidiabetic Medications
• Patients inadequately controlled by diet and exercise alone

Key Benefits

• Helps control postprandial blood glucose levels.
• Rapid onset of action for mealtime glucose management.
• Stimulates insulin secretion in response to meals.
• Can be used alone or in combination with other antidiabetic medications.
• Supports effective long-term glycemic control.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured in accordance with stringent pharmaceutical quality standards. Reepag 1 undergoes comprehensive quality assurance and rigorous testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Reepag 1 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.